Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3)

NCT04040322 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

198

Enrollment

INDUSTRY

Sponsor class

Conditions

Raynaud's Phenomenon Secondary to Systemic Sclerosis

Interventions

DRUG: Placebo IV infusion
DRUG: Iloprost Injection, for intravenous use

Sponsor

Civi Biopharma, Inc.